Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Heinzerling, Lucie
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)	Active, not recruiting	3	407	Europe, US, RoW	IO102-IO103, Pembrolizumab	IO Biotech, Syneos Health, Merck Sharp & Dohme LLC	Metastatic Melanoma, Unresectable Melanoma	07/25	09/27
PROMIT, NCT04225390: Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy	Recruiting	2	38	Europe	Dacarbazine (DTIC), DTIC	University of Erlangen-Nürnberg Medical School, University Hospital Regensburg, Wuerzburg University Hospital	Immunotherapy	06/23	07/23
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma	Active, not recruiting	2	220	Europe, US, RoW	Botensilimab, AGEN1181, Balstilimab, AGEN2034	Agenus Inc.	Advanced Melanoma	05/28	05/28
PRIA, NCT05700565: Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype	Recruiting	N/A	50	Europe	Extracorporeal photopheresis, Other immunosuppressive or immunomodulatory drugs	Lucie Heinzerling	Immune-related Adverse Event	01/27	01/27